Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Ligustrazine in Treating Alcohol Addiction

NCT05942352 is registered in ClinicalTrials.gov with Shenzhen Kangning Hospital as lead sponsor.

NCT NCT05942352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05942352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Ligustrazine in Treating Alcohol Addiction
Lead sponsor
Shenzhen Kangning Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
July 28, 2023
Completion date
July 31, 2024
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol abuse, arteriosclerosis